Friday , June 22 2018
Home / Osteoarthritis

Osteoarthritis

Anika’s Drug Combo Fails to Meet Primary Endpoint in Phase 3 Trial in Knee Osteoarthritis

BEDFORD, Mass.–(BUSINESS WIRE)–Jun. 19, 2018– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology platform, today announced results from its CINGAL® 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration. CINGAL has previously been evaluated …

Read More »

Centrexion Therapeutics’ CNTX-4975 Receives Fast Track Designation from the FDA for Treatment of Knee Osteoarthritis Pain

BOSTON–(BUSINESS WIRE)–Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CNTX-4975 for the treatment of pain associated with knee osteoarthritis. CNTX-4975, Centrexion’s Phase 3 ready lead therapy, is a …

Read More »

Ampio Pharmaceuticals Announces Positive Late-Stage Results for its Knee Osteoarthritis Drug

ENGLEWOOD, Colo., Dec. 14, 2017 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported that the Phase 3 clinical trial of Ampion™ met its primary endpoint with 71% of Ampion™ treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment …

Read More »

Bioventus Receives FDA Approval for Durolane for Treatment of Pain Associated with Knee Osteoarthritis

DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologic solutions, today announced it has received US FDA approval for DUROLANE, a single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis (OA). Hyaluronic acid is a naturally occurring molecule that provides the lubrication and …

Read More »

Servier Licenses GLPG1972 in Osteoarthritis from Galapagos

28 July 2017 – As a result of their research collaboration, Servier announces today that it has exercised its option to develop novel osteoarthritis molecule GLPG1972/S201086 from Galapagos NV (Euronext/NASDAQ: GLPG), thus obtaining global commercial rights outside the U.S. Osteoarthritis (OA) is a highly prevalent and disabling pathology, considered as …

Read More »

Anika Therapeutics’ Cingal Wins CE Mark Approval for Pain Associated with Osteoarthritis of the Knee

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid “HA” technology, today announced that it received CE Mark approval for CINGAL® as a medical device to treat pain associated with osteoarthritis of the knee. CINGAL is the …

Read More »